Adrenomed, MYND Life Sciences, Inotrem, Vivacelle Bio,
Palisade Bio, Baxter Healthcare Corporation, RegeneRx Biopharmaceuticals, Pharmazz, Inc., La Jolla Pharmaceutical, and others are developing potential drug candidates to improve the Septic Shock treatment scenario.
Key Septic shock pipeline candidates such as
Adrecizumab,
Nangibotide,
Tranexamic acid, Timbetasin, VBI-S, OctaplasLG, and others are under investigation in different phases of clinical trials to treat Septic shock.
Adrecizumab is a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is bolstered by the elegance of its mode of action. This monoclonal antibody on binding to its target Adrenomedullin preserves its functionality as a regulator of vascular integrity. Adrecizumab is currently under clinical evaluation. In the AdrenOSS-2, proof-of-concept phase II trial in septic shock, Adrecizumab shown a favorable safety profile, was well tolerated and established a trend in survival for Adrecizumab-treated patients compared to placebo. Favorable safety and tolerability were already shown in previous Phase I trials. The company is preparing to initiate a phase IIb/III trial in early 2022.